Kyorin Pharmaceutical Co (TSE:4569) Additional Paid-In Capital : 円4,752 Mil(As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Additional Paid-In Capital?

Kyorin Pharmaceutical Co's quarterly additional paid-in capital stayed the same from Jun. 2023 (円4,752 Mil) to Sep. 2023 (円4,752 Mil) and stayed the same from Sep. 2023 (円4,752 Mil) to Dec. 2023 (円4,752 Mil).

Kyorin Pharmaceutical Co's annual additional paid-in capital stayed the same from Mar. 2021 (円4,752 Mil) to Mar. 2022 (円4,752 Mil) and stayed the same from Mar. 2022 (円4,752 Mil) to Mar. 2023 (円4,752 Mil).

Kyorin Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Additional Paid-In Capital Chart

Kyorin Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Additional Paid-In Capital

Get a 7-Day Free Trial

4,752.00

Kyorin Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															4,752.00	4,752.00	4,752.00	4,752.00	4,752.00

Kyorin Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Kyorin Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyorin Pharmaceutical Co (TSE:4569) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311

Website

https://www.kyorin-pharm.co.jp

Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines